Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells

Suzuki,Toshihiro; Ishibashi,Kenichi; Yumoto,Atsushi; Nishio,Kazuto; Ogasawara,Yuki

doi:10.3892/ol.2015.3352

Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells

Authors:
- Toshihiro Suzuki
- Kenichi Ishibashi
- Atsushi Yumoto
- Kazuto Nishio
- Yuki Ogasawara
View Affiliations

Affiliations: Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose, Tokyo 204‑8588, Japan, Department of Genome Biology, Kinki University School of Medicine, Osaka‑sayama, Osaka 589‑8511, Japan
Published online on: June 10, 2015 https://doi.org/10.3892/ol.2015.3352
Pages: 805-809
Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is a commonly used drug in combination chemotherapy. However, various malignant tumors frequently acquire resistance to cisplatin. Arsenic trioxide (ATO) has been approved as a chemotherapeutic drug for the treatment of acute promyelocytic leukemia, and the combination of ATO and cisplatin has been revealed to demonstrate synergistic effects in ovarian and small cell lung cancer cells. Thus, it was hypothesized that ATO may also be active against cisplatin‑resistant non‑small cell lung cancer (NSCLC) PC‑9/CDDP and PC‑14/CDDP cells. The present study also evaluated the effects of ATO on the cisplatin‑sensitive NSCLC PC‑9 and PC‑14 cell lines. Notably, ATO demonstrated a markedly decreased IC50 in the cisplatin‑resistant PC‑9/CDDP and PC‑14/CDDP cells compared with the IC50 in the cisplatin‑sensitive parental PC‑9 and PC‑14 cells. Additionally, it was found that arsenite accumulation in the PC‑9 cell line was affected through the downregulation of GS‑X pump systems. Although it is likely that cisplatin resistance in PC‑9 cells does not depend on the GS‑X pump systems, ATO was effective against cisplatin-resistant NSCLC PC-9/CDDP and PC-14/CDDP cells in combination chemotherapy.

View Figures

View References

1	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin Oncol. 11:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
3	Suzuki T, Nishio K and Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab. 2:367–377. 2001. View Article : Google Scholar : PubMed/NCBI
4	Nordstrom DK: Public health. Worldwide occurrences of arsenic in ground water. Science. 296:2143–2145. 2002. View Article : Google Scholar : PubMed/NCBI
5	Rao Y, Li R and Zhang D: A drug from poison: How the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci China Life Sci. 56:495–502. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lengfelder E, Hofmann WK and Nowak D: Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 26:433–442. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zhang N, Wu ZM, McGowan E, Shi J, Hong ZB, Ding CW, Xia P and Di W: Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: Therapeutic potential for ovarian cancer. Cancer Sci. 100:2459–2464. 2009. View Article : Google Scholar : PubMed/NCBI
8	Helm CW and States JC: Enhancing the efficacy of cisplatin in ovarian cancer treatment-could arsenic have a role. J Ovarian Res. 2:22009. View Article : Google Scholar : PubMed/NCBI
9	Zheng CY, Lam SK, Li YY, Fong BM, Mak JC and Ho JC: Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Lung Cancer. 82:222–230. 2013. View Article : Google Scholar : PubMed/NCBI
10	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
11	Leslie EM: Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). J Inorg Biochem. 108:141–149. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K and Twentyman PR: Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 41:462–467. 1988. View Article : Google Scholar : PubMed/NCBI
13	Uemura M, Suzuki T, Nishio K, Chikuma M and Komeda S: An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum (II) complex largely circumvents in vitro cisplatin resistance: Two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles. Metallomics. 4:686–692. 2012. View Article : Google Scholar : PubMed/NCBI
14	Mukai Y, Togawa T, Suzuki T, Ohata K and Tanabe S: Determination of homocysteine thiolactone and homocysteine in cell cultures using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 767:263–268. 2002. View Article : Google Scholar : PubMed/NCBI
15	Habig WH, Pabst MJ, Fleischner G, Gatmaitan Z, Arias IM and Jakoby WB: The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc Natl Acad Sci USA. 71:3879–3882. 1974. View Article : Google Scholar : PubMed/NCBI
16	Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H and Soda H: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 110:921–927. 2004. View Article : Google Scholar : PubMed/NCBI
17	Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M and Saijo N: Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Comm. 216:258–264. 1995. View Article : Google Scholar : PubMed/NCBI
18	Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD and Kuo MT: Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. The Journal of biological chemistry. 271:14981–14988. 1996. View Article : Google Scholar : PubMed/NCBI
19	Naredi P, Heath DD, Enns RE and Howell SB: Cross-resistance between cisplatin, antimony potassium tartrate and arsenite in human tumor cells. J Clin Invest. 95:1193–1198. 1995. View Article : Google Scholar : PubMed/NCBI
20	Suzuki T, Ohata S, Togawa T, Himeno S and Tanabe S: Arsenic accumulation decreased in metallothionein null Cisplatin-resistant cell lines. J Toxicol Sci. 32:321–328. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nakaoka T, Ota A, Ono T, Karnan S, Konishi H, Furuhashi A, Ohmura Y, Yamada Y, Hosokawa Y, Kazaoka Y, et al: Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell Oncol (Dordr). 37:119–129. 2014. View Article : Google Scholar : PubMed/NCBI
22	Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P and Rosen BP: Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA. 99:6053–6058. 2002. View Article : Google Scholar : PubMed/NCBI